91 related articles for article (PubMed ID: 2516403)
21. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.
Nastala CL; Edington HD; McKinney TG; Tahara H; Nalesnik MA; Brunda MJ; Gately MK; Wolf SF; Schreiber RD; Storkus WJ
J Immunol; 1994 Aug; 153(4):1697-706. PubMed ID: 7913943
[TBL] [Abstract][Full Text] [Related]
22. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.
Spiess PJ; Yang JC; Rosenberg SA
J Natl Cancer Inst; 1987 Nov; 79(5):1067-75. PubMed ID: 3500355
[TBL] [Abstract][Full Text] [Related]
23. Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts.
Murphy WJ; Back TC; Conlon KC; Komschlies KL; Ortaldo JR; Sayers TJ; Wiltrout RH; Longo DL
J Clin Invest; 1993 Oct; 92(4):1918-24. PubMed ID: 8408644
[TBL] [Abstract][Full Text] [Related]
24. Recombinant human interleukin-11 improved carboplatin-induced thrombocytopenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells.
Saitoh M; Taguchi K; Momose K; Suga K; Yamazaki N; Ono C; Suzuki T; Takeuchi O; Yasuda S; Miyata K
Cancer Chemother Pharmacol; 2002 Feb; 49(2):161-6. PubMed ID: 11862431
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory effect of murine recombinant interferon (beta) on the pulmonary metastasis of B-16 melanoma.
Sakurai M; Iigo M; Ozaki A; Jett JR; Sasaki Y; Hoshi A; Saijo N
Jpn J Cancer Res; 1986 Aug; 77(8):774-81. PubMed ID: 3093426
[TBL] [Abstract][Full Text] [Related]
26. Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells.
Hinuma S; Naruo K; Ootsu K; Houkan T; Shiho O; Tsukamoto K
Immunology; 1987 Feb; 60(2):173-9. PubMed ID: 3493209
[TBL] [Abstract][Full Text] [Related]
27. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.
Manda T; Shimomura K; Mukumoto S; Kobayashi K; Mizota T; Hirai O; Matsumoto S; Oku T; Nishigaki F; Mori J
Cancer Res; 1987 Jul; 47(14):3707-11. PubMed ID: 3594435
[TBL] [Abstract][Full Text] [Related]
28. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
Li J; Hu P; Khawli LA; Epstein AL
Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
[TBL] [Abstract][Full Text] [Related]
29. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha.
McIntosh JK; Mulé JJ; Merino MJ; Rosenberg SA
Cancer Res; 1988 Jul; 48(14):4011-7. PubMed ID: 3260130
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-beta gene and poly I: poly C in a murine lung metastasis model.
Sakurai F; Terada T; Maruyama M; Watanabe Y; Yamashita F; Takakura Y; Hashida M
Cancer Gene Ther; 2003 Sep; 10(9):661-8. PubMed ID: 12944985
[TBL] [Abstract][Full Text] [Related]
31. Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma.
Zhang R; Tian L; Chen LJ; Xiao F; Hou JM; Zhao X; Li G; Yao B; Wen YJ; Li J; Zhang L; Chen XC; Luo F; Peng F; Jiang Y; Wei YQ
Gene Ther; 2006 Sep; 13(17):1263-71. PubMed ID: 16672984
[TBL] [Abstract][Full Text] [Related]
32. Inability of recombinant interferon-gamma to activate the antibacterial activity of mouse peritoneal macrophages against Listeria monocytogenes and Salmonella typhimurium.
van Dissel JT; Stikkelbroeck JJ; Michel BC; van den Barselaar MT; Leijh PC; van Furth R
J Immunol; 1987 Sep; 139(5):1673-8. PubMed ID: 2957433
[TBL] [Abstract][Full Text] [Related]
33. Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo.
Kase S; Kubota T; Watanabe M; Furukawa T; Tanino H; Ishibiki K; Teramoto T; Kitajima M
Anticancer Res; 1993; 13(2):369-73. PubMed ID: 8517649
[TBL] [Abstract][Full Text] [Related]
34. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
[TBL] [Abstract][Full Text] [Related]
35. [In vitro enhancement of cytotoxicity of human peripheral blood lymphocytes with recombinant interleukin 2 and an interferon mixture (alpha + beta + gamma) against human colon carcinoma cell line SW1116].
Kimoto Y
Gan To Kagaku Ryoho; 1986 Dec; 13(12):3419-26. PubMed ID: 3098183
[TBL] [Abstract][Full Text] [Related]
36. Enhanced antitumor effect of combination therapy with interleukin-2 and polyribonucleotides against adenocarcinoma 755.
Iigo M; Nakajima Y; Nishikata K; Hoshi A
J Biol Response Mod; 1989 Apr; 8(2):147-54. PubMed ID: 2786554
[TBL] [Abstract][Full Text] [Related]
37. In vivo and in vitro activation of alveolar macrophages by recombinant interferon-gamma.
Black CM; Catterall JR; Remington JS
J Immunol; 1987 Jan; 138(2):491-5. PubMed ID: 3098846
[TBL] [Abstract][Full Text] [Related]
38. Interferon inhibition of IL-2-mediated lymphocyte proliferation.
Kim B; Franceschi D; Helman S; Cleveland RP; Imbembo AL
Surgery; 1988 Aug; 104(2):390-7. PubMed ID: 2969632
[TBL] [Abstract][Full Text] [Related]
39. Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Separation of efficacy and toxicity by selective lymphocyte subset depletion.
Anderson TD; Hayes TJ; Gately MK; Bontempo JM; Stern LL; Truitt GA
Lab Invest; 1988 Nov; 59(5):598-612. PubMed ID: 3263543
[TBL] [Abstract][Full Text] [Related]
40. Induction and persistence in vivo of NK/LAK activity by a mannoprotein component of Candida albicans cell wall.
Scaringi L; Cornacchione P; Rosati E; Fettucciari K; Rossi R; Marconi P
Cell Immunol; 1994 May; 155(2):265-82. PubMed ID: 8181065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
